Quote this publication Share Print


Opinions on drugs - Posted on Mar 28 2012

Reason for request

Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication: “treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease”.


Clinical Benefit


The actual benefit of AFINITOR is substantial.

Clinical Added Value


AFINITOR provides a minor IAB (level IV) in terms of efficacy in the therapeutic management of patients with advanced neuroendocrine tumours of pancreatic origin.

Contact Us

Évaluation des médicaments

See also